Clinical trials: Lymphatic Disease
Blood Coagulation Disorders
The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
This proposal is designed to mitigate hemodilution (blood diluted with an electrolyte solution) and loss of plasma proteins responsible for normal blood clotting as well as platelets at the completion of cardiopulmonary bypass…
- Trial name
- NCT01435304
- Testing
- method of returning residual CPB blood ( Hemobag®)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies
This is a pilot study to evaluate the use feasibility of the iThermonitor, a continuous temperature monitoring device, as a clinical support and patient self-management tool in the management of pediatrics patients on…
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT02410252
- Testing
- iThermonitor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Anaemia
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)
This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) participants with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on…
- Trial name
- NCT03029247
- Testing
- Daprodustat, Epoetin alfa
- Where
- 11 sites in United States
- Volunteers
- 105 people
- Sponsor
- GlaxoSmithKline
Enlarged Lymph Nodes (Excluding Infective)
Evaluation of 19-gauge vs 21-gauge EBUS TBNA in Assessing Thoracic Lymphadenopathy
This study compares the yield of 19-gauge needles vs 21-gauge needles during EBUS TBNA procedures.
- Trial name
- NCT03657849
- Testing
- EBUS TBNA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- HealthPartners Institute
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Iron Deficiency Anaemia, Iron Deficiency Anemia
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
- Trial name
- NCT03237065
- Testing
- Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Pharmacosmos A/S
Anemia, Anemia of Cancer
Darbepoetin Alfa and Anemia of Cancer
This phase 2, multicenter, randomized, open-label, comparative study was designed to determine the effect of darbepoetin alfa on hospital days, economic outcomes, and health related quality of life (HRQOL) in anemic patients with…
- Conditions
- Anemia, Anemia of Cancer, Cancer, Carcinoma
- Trial name
- NCT00989092
- Testing
- darbepoetin alfa
- Volunteers
- 287 people
- Sponsor
- Amgen
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL).
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT01361711
- Testing
- alemtuzumab, ofatumumab, biopsy
- Where
- 2 sites in United States, Sweden
- Volunteers
- 53 people
- Sponsor
- Northwestern University
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
The primary purpose of this study is to estimate the major cytogenetic response rates of BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome positive, chronic myeloid leukemia (PH+ CML) with…
- Trial name
- NCT00103844
- Testing
- Dasatinib, Imatinib
- Where
- 131 sites in United States, Argentina and 30 more
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Anemia
ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
The purpose of this study is to determine if there is a difference in outcomes between liberal transfusion (transfusing when hemoglobin drops below a set higher value number) and conservative transfusion (transfusing when…
- Trial name
- ORACL (NCT02972593)
- Testing
- Blood and blood products for transfusion
- Volunteers
- 161 people
- Sponsor
- Indiana University
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active.
- Trial name
- NCT01085214
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with…
- Trial name
- NCT01909934
- Testing
- Brentuximab vedotin
- Where
- 40 sites in Belgium, Croatia and 8 more
- Volunteers
- 50 people
- Sponsor
- Takeda
Hepatitis C
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count.
- Trial name
- ENABLE-ALL (NCT00996216)
- Testing
- Eltrombopag, Antiviral therapy
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Thrombocythemia, Hemorrhagic
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots.
- Trial name
- NCT00202644
- Testing
- Anagrelide, Hydroxyurea
- Where
- 15 sites in Bulgaria, France and 4 more
- Volunteers
- 150 people
- Sponsor
- Shire
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Multiple Myeloma, Leukemia, Plasma Cell
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Background: Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant.
- Trial name
- NCT01658904
- Testing
- Carfilzomib, Melphalan, Filgrastim
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Patient Participation
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
The median overall survival (OS) of relapsed/refractory multiple myeloma (MM) is less than nine months. However, phase II data with the proteasome inhibitor bortezomib (Velcade®) has been heartening, with 35% overall response…
- Trial name
- DMV (NCT00985907)
- Testing
- Doxil, melphalan, bortezomib
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.